Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 9Breast Neoplasms 5Sarcoma 4Recurrence 4Neoplasm Metastasis 4Lymphoma 4Solid Tumors 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Glioblastoma 2Endometrial Neoplasms 2Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Advanced Cancers 1

Interventions

pembrolizumab 44Paclitaxel 37Carboplatin 30Doxorubicin 11Cisplatin 11Bevacizumab 11lenvatinib 9Nivolumab 9Docetaxel 9Fulvestrant 8Gemcitabine 7Oxaliplatin 6Fluorouracil 6Pemetrexed 5Letrozole 5Ipilimumab 5Cetuximab 5spartalizumab 4selinexor 4dostarlimab 4Trastuzumab 4Irinotecan 4trastuzumab deruxtecan 3tisotumab vedotin 3serabelisib 3sacituzumab govitecan 3ribociclib 3olaparib 3epacadostat 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Endometrial Neoplasms × ridaforolimus × Clear all
NCT00739830 2015-07-01

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Merck Sharp & Dohme LLC

Phase 2 Completed
130 enrolled
Gynecologic

Endometrial Neoplasms

NCT00122343 2015-02-19

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
45 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡